VolitionRx (VNRX) announced the preparation of the reimbursement submission for its Nu.Q Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon, France’s second largest university hospital system, and will run in parallel with the process to achieve clinical certification of the test at HCL. The Innovative Procedures Outside the Nomenclature framework allows for the early and temporary support of innovative procedures.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- VolitionRx adds two laboratories providing its vet cancer test in U.S. and Asia
- VolitionRx announces clinical data for Nu.Q Vet cancer test in cats
- VolitionRX Announces CEO Departure Amid Cost Realignment
- VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment
- VolitionRX Gains Momentum with Strategic Advancements in Sepsis and Cancer Diagnostics